Global Down Syndrome

2019 Issue 1 of 4

Issue link: https://viewer.e-digitaledition.com/i/1111717

Contents of this Issue

Navigation

Page 11 of 27

SNPs POTENTIAL TARGETS FOR IMPROVING MEMORY AND COGNITION The endocannabinoid system plays an important role in learning and memory, as well as the endocrine and immune systems. Previous research has found that drugs that target cannabinoid receptor type-1 (CB1R) have the potential to treat neurological disorders, such as Alzheimer's disease and epilepsy. Researchers from Universitat Pompeu Fabra Barcelona recently found that such medications show promise in improving memory and cognition in Down syndrome. Using two types of Down syndrome mouse models, they learned that CB1R inhibitors not only restored memory deficits and improved cognitive performance, but also boosted synaptic plasticity (which influences how memories are stored and created) and neurogenesis (the growth of new neurons) in the mice. Navarro-Romero, et. al. Neurobiology of Disease, Jan. 2019 (e-pub); 125:92-106 CORRECTING VISION PROBLEMS EARLY IN LIFE Children with Down syndrome frequently experience vision problems, but there is little consensus among eye health practitioners about when parents should first have their children with Down syndrome evaluated. In this small study, Italian researchers had 42 children with Down syndrome undergo two forms of vision testing. One test, the Early Neurovisual Assessment, was conducted at 6, 12, and 18 months of age, and the second, the Pediatric Ophthalmological Examination, at 36 months. Their results suggest that administering the Early Neurovisual Assessment at 18 months was an optimal tool for identifying and addressing vision problems early enough to allow for proper neurodevelopment. Purpura, et. al. Early Human Development, Feb. 2019 (e-pub); 131:21-28

Articles in this issue

Links on this page

Archives of this issue

view archives of Global Down Syndrome - 2019 Issue 1 of 4